Semaglutide results at 3 months: what clinical evidence actually shows

What the STEP 1 trial data shows at the three-month point

The clearest picture of early semaglutide results comes from the STEP 1 trial, a 68-week study published in the New England Journal of Medicine, involving 1,961 adults with obesity or overweight and at least one weight-related condition, without diabetes. Participants on semaglutide 2.4mg lost an average of around 14.9% of body weight over the full trial, but the trajectory matters as much as the endpoint.

At the 12-week mark, most participants were still on a sub-maintenance dose. The semaglutide titration schedule moves through 0.25mg, 0.5mg, 1.0mg and 1.7mg before reaching 2.4mg, with roughly four weeks at each level. So at three months, the majority of the trial group had only just moved onto the 1.0mg phase. Weight loss was already measurable and meaningful for many, but the medicine had not yet reached its working ceiling.

Trial analyses suggest around 5–9% average loss by week 12–16, though this varied between participants. Those who responded most strongly in the first eight weeks tended to sustain higher overall losses. This early-response pattern is one reason prescribers monitor progress at the three-month review: it provides useful signal, not a final verdict. If you are curious how results develop slightly earlier, semaglutide at two months covers the picture during that initial titration phase.

Why three months is mid-journey, not the milestone it can feel like

There is a natural tendency to treat the three-month point as a report card. Many people have been on the medicine for a quarter of a year; it feels like enough time. In practice, the pharmacology tells a different story. The licensed timeline for Wegovy to work at full effect assumes you have been at 2.4mg (or now potentially 7.2mg) long enough for appetite suppression to fully stabilise, which typically happens some weeks after reaching maintenance dose.

At three months, many people are either just arriving at 1.7mg or making the final step to 2.4mg. Some will have had pauses or slower titration because of gastrointestinal side effects, nausea and loose stools are common early on, particularly after each dose increase, and a prescriber may hold a dose for longer to let the body settle. That is not a setback; it is the medicine being used safely.

The practical upshot is that progress at three months should be read as a trend rather than a destination. Losing 5% of body weight in twelve weeks is clinically meaningful (it represents real change in metabolic risk) but the same person may go on to lose twice that over the following six months. Detailed outcomes at this stage are worth reading alongside what happens as titration completes.

Factors that shape individual results by month three

No two people experience the same three-month result, and the STEP 1 averages deliberately hide the range. Several factors consistently influence how much weight someone loses in the first quarter of treatment.

Dose reached matters most. Someone who reached 2.4mg at eight weeks (rare, but possible in people with high tolerability) will have had more exposure to the maintenance dose than someone still at 1.0mg. Starting body weight is a second factor: people with a higher BMI often see a larger absolute loss in kilograms, even when the percentage is similar. Diet quality alongside treatment plays a real role too, semaglutide reduces appetite but does not override calorie intake entirely, and the NHS guidance on obesity treatment consistently emphasises that behavioural changes sit alongside, not beneath, any medicine.

Physical activity, sleep, stress and underlying conditions all contribute. A question our prescribers hear regularly is whether slower early progress means the medicine is not working. Usually it does not, the body's response to GLP-1 receptor agonism takes time, and even modest early weight loss often signals that appetite suppression is beginning to take hold. Anyone with specific concerns about their progress should raise them with their prescriber rather than adjusting treatment independently. If you are weighing up costs alongside expectations, our page on Wegovy pricing in the UK gives context on what to look for in a legitimate private prescription service.

What three months of results tell you about the longer road

Research consistently shows that early response to semaglutide predicts (but does not guarantee) longer-term outcome. Participants who lost at least 5% of body weight by week 16 in STEP 1 went on to achieve substantially greater total losses than those who did not reach that threshold. This is why the prescriber review at or around the six-month mark (on the NICE-recommended pathway for semaglutide) assesses whether treatment is delivering enough benefit to continue, less than 5% loss after six months at maintenance dose is a trigger to reconsider.

By month three you are not yet at that review point, but you are building evidence. Keeping a simple weight log (even just stepping on the scales on the same morning each week before breakfast, the way you might check in before the day properly starts) gives your prescriber the data they need at follow-up. Tracking how your appetite and portion sizes have changed is equally useful, because the medicine works on satiety signals that are not always fully reflected on the scales yet.

For a longer view of the trajectory, the pharmacokinetics of semaglutide and what happens when treatment stops are both worth understanding before making decisions about continuing or pausing. If you are ready to discuss your progress or start treatment for the first time, our prescribers can review your case the same day.